Lessons from clinical trials on triple combination of immune checkpoint inhibitors and BRAF/MEK inhibitors in BRAF-mutant melanoma

Detalles Bibliográficos
Autores principales: Maeda, Takuya, Yanagi, Teruki, Ujiie, Hideyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Editorial Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316103/
https://www.ncbi.nlm.nih.gov/pubmed/37405002
http://dx.doi.org/10.21037/atm-23-1215
_version_ 1785067643045150720
author Maeda, Takuya
Yanagi, Teruki
Ujiie, Hideyuki
author_facet Maeda, Takuya
Yanagi, Teruki
Ujiie, Hideyuki
author_sort Maeda, Takuya
collection PubMed
description
format Online
Article
Text
id pubmed-10316103
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-103161032023-07-04 Lessons from clinical trials on triple combination of immune checkpoint inhibitors and BRAF/MEK inhibitors in BRAF-mutant melanoma Maeda, Takuya Yanagi, Teruki Ujiie, Hideyuki Ann Transl Med Editorial Commentary AME Publishing Company 2023-04-04 2023-06-30 /pmc/articles/PMC10316103/ /pubmed/37405002 http://dx.doi.org/10.21037/atm-23-1215 Text en 2023 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Editorial Commentary
Maeda, Takuya
Yanagi, Teruki
Ujiie, Hideyuki
Lessons from clinical trials on triple combination of immune checkpoint inhibitors and BRAF/MEK inhibitors in BRAF-mutant melanoma
title Lessons from clinical trials on triple combination of immune checkpoint inhibitors and BRAF/MEK inhibitors in BRAF-mutant melanoma
title_full Lessons from clinical trials on triple combination of immune checkpoint inhibitors and BRAF/MEK inhibitors in BRAF-mutant melanoma
title_fullStr Lessons from clinical trials on triple combination of immune checkpoint inhibitors and BRAF/MEK inhibitors in BRAF-mutant melanoma
title_full_unstemmed Lessons from clinical trials on triple combination of immune checkpoint inhibitors and BRAF/MEK inhibitors in BRAF-mutant melanoma
title_short Lessons from clinical trials on triple combination of immune checkpoint inhibitors and BRAF/MEK inhibitors in BRAF-mutant melanoma
title_sort lessons from clinical trials on triple combination of immune checkpoint inhibitors and braf/mek inhibitors in braf-mutant melanoma
topic Editorial Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316103/
https://www.ncbi.nlm.nih.gov/pubmed/37405002
http://dx.doi.org/10.21037/atm-23-1215
work_keys_str_mv AT maedatakuya lessonsfromclinicaltrialsontriplecombinationofimmunecheckpointinhibitorsandbrafmekinhibitorsinbrafmutantmelanoma
AT yanagiteruki lessonsfromclinicaltrialsontriplecombinationofimmunecheckpointinhibitorsandbrafmekinhibitorsinbrafmutantmelanoma
AT ujiiehideyuki lessonsfromclinicaltrialsontriplecombinationofimmunecheckpointinhibitorsandbrafmekinhibitorsinbrafmutantmelanoma

Ejemplares similares